Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | SLC5A2 | P31639 | 6/20 | 0.42 |
| ▸ | GALR3 | O60755 | 1/20 | 0.41 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | ADK | P55263 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.35 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2154637 | 1.00 | PDE4D (0.44) | PDE4DSLC5A2GALR3NR2F2TSHR | |
| SCHEMBL12671725 | 1.00 | PDE4D (0.44) | PDE4DSLC5A2GALR3NR2F2TSHR | |
| SCHEMBL15492630 | 1.00 | PDE4D (0.44) | PDE4DSLC5A2GALR3NR2F2TSHR | |
| SCHEMBL20857297 | 1.00 | PDE4D (0.44) | PDE4DSLC5A2GALR3NR2F2TSHR | |
| SCHEMBL14389130 | 1.00 | PDE4D (0.44) | PDE4DSLC5A2GALR3NR2F2TSHR | |
| SCHEMBL14211491 | 0.90 | SLC5A2 (0.44) | PDE4DSLC5A2GALR3NR2F2ADK | |
| SCHEMBL14088381 | 0.90 | SLC5A2 (0.44) | PDE4DSLC5A2GALR3NR2F2ADK | |
| SCHEMBL18025721 | 0.90 | SLC5A2 (0.44) | PDE4DSLC5A2GALR3NR2F2ADK | |
| SCHEMBL14089081 | 0.90 | SLC5A2 (0.44) | PDE4DSLC5A2GALR3NR2F2ADK | |
| SCHEMBL14234013 | 0.90 | SLC5A2 (0.44) | PDE4DSLC5A2GALR3NR2F2ADK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2212696-B1 | SYSTEMS AND METHODS FOR VIRAL THERAPY | GENELUX CORP (US) | 2013-12-04 | — | — | EP | disclosed |
| US-8450469-B2 | Synthesis of peptide nucleic acids conjugated with amino acids and their application | PANAGENE INC. (KR) | 2013-05-28 | — | — | US | disclosed |
| US-20110014715-A1 | Synthesis of Peptide Nucleic Acids Conjugated with Amino Acids and Their Application | PANAGENE INC. (KR) | 2011-01-20 | — | — | US | disclosed |
| US-20100292471-A1 | PEPTIDE NUCLEIC ACID OLIGOMERS COMPRISING UNIVERSAL BASES,PREPARATION METHODS THEREOF, AND KITS, DEVICES AND METHODS FOR THE ANALYSIS, DETECTION OR MODULATION OF NUCLEIC ACIDS USING THE SAME | PANAGENE INC. (KR) | 2010-11-18 | — | — | US | disclosed |
| EP-2094863-A1 | PEPTIDE NUCLEIC ACID OLIGOMERS COMPRISING UNIVERSAL BASES, PREPARATION METHODS THEREOF, AND KITS, DEVICES AND METHODS FOR THE ANALYSIS, DETECTION OR MODULATION OF NUCLEIC ACIDS USING THE SAME | Panagene, Inc. (KR) | 2009-09-02 | — | — | EP | disclosed |
| US-20090136917-A1 | Systems and methods for viral therapy | GENELUX CORPORATION | 2009-05-28 | — | — | US | disclosed |
| WO-2008075871-A1 | PEPTIDE NUCLEIC ACID OLIGOMERS COMPRISING UNIVERSAL BASES, PREPARATION METHODS THEREOF, AND KITS, DEVICES AND METHODS FOR THE ANALYSIS, DETECTION OR MODULATION OF NUCLEIC ACIDS USING THE SAME | PANAGENE INC. (KR) | 2008-06-26 | — | — | WO | disclosed |
| US-7368475-B2 | Furanose-type bicyclic carbohydrates with biological activity | KEMIN PHARMA BVBA (US) | 2008-05-06 | — | — | US | disclosed |
| US-7368475-B2 | Furanose-type bicyclic carbohydrates with biological activity | KEMIN PHARMA BVBA (US) | 2008-05-06 | — | — | US | disclosed |
| US-20050026189-A1 | Microbial operons | MERCK & CO., INC. | 2005-02-03 | — | — | US | disclosed |
| US-20040220251-A1 | Furanose-type bicyclic carbohydrates with biological activity | KEMIN PHARMA EUROPE B.V.B.A. | 2004-11-04 | — | — | US | disclosed |
| US-6720139-B1 | PRODUCING A SENSITIZED CELL BY EXPRESSING AN ANTISENSE NUCLEIC ACID AGAINST A NUCLEIC ACID ENCODING A GENE PRODUCT; CONTACTING THE CELL WITH A CANDIDATE COMPOUND; COMPARING GROWTH INHIBITION TO THAT OF A NONSENSITIZED CELL | ELITRA PHARMACEUTICALS, INC. | 2004-04-13 | — | — | US | disclosed |
| US-20040029129-A1 | Identification of essential genes in microorganisms | MERCK & CO., INC. | 2004-02-12 | — | — | US | disclosed |
| US-20030181408-A1 | Genes essential for microbial proliferation and antisense thereto | MERCK & CO., INC. | 2003-09-25 | — | — | US | disclosed |
| US-20030170694-A1 | Stabilized nucleic acids in gene and drug discovery and methods of use | MERCK & CO., INC. | 2003-09-11 | — | — | US | disclosed |
| US-6589738-B1 | Expressing a sublethal level of an antisense nucleic acid complementary to a nucleic acid encoding said gene to reduce its activity; drug screening; antibiotics | ELITRA PHARMACEUTICALS, INC. | 2003-07-08 | — | — | US | disclosed |
| US-20020061569-A1 | Identification of essential genes in prokaryotes | MERCK & CO., INC. | 2002-05-23 | — | — | US | disclosed |
| US-20020045592-A1 | Genes identified as required for proliferation in escherichia coli | ELITRA PHARMACEUTICALS, INC. | 2002-04-18 | — | — | US | disclosed |
| US-20020022718-A1 | Genes identified as required for proliferation of E. coli | MERCK & CO., INC. | 2002-02-21 | — | — | US | disclosed |
| EP-1178052-A2 | Genes identified as required for proliferation in Escherichia coli | Elitra Pharmaceuticals, Inc. (US) | 2002-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220251-A1 | Furanose-type bicyclic carbohydrates with biological activity | MANBA, FBP1, GALE | PDE4D 2735/4885SLC5A2 689/4885GALR3 2323/4885 |
| US-20100292471-A1 | PEPTIDE NUCLEIC ACID OLIGOMERS COMPRISING UNIVERSAL BASES,PREPARATION METHODS THEREOF, AND KITS, DEVICES AND METHODS FOR THE ANALYSIS, DETECTION OR MODULATION OF NUCLEIC ACIDS USING THE SAME | ADAR, POLM, POLRMT | PDE4D 2421/4885SLC5A2 4024/4885GALR3 3261/4885 |
| US-20110014715-A1 | Synthesis of Peptide Nucleic Acids Conjugated with Amino Acids and Their Application | CPSF6, RNGTT, DNPEP | PDE4D 4111/4885SLC5A2 2800/4885GALR3 2502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.